search
Back to results

Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Primary Purpose

Recurrent Platinum-sensitive Ovarian Cancer

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Carboplatin
PLD
Bevacizumab
Sponsored by
AGO Research GmbH
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Recurrent Platinum-sensitive Ovarian Cancer focused on measuring Ovarian Carcinoma, Bevacizumab, Gemcitabine, PLD, pegylated liposomal doxorubicin, Carboplatin, best therapeutic index, progression-free survival

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Histologically confirmed diagnosis of epithelial ovarian carcinoma or fallopian tube carcinoma or primary peritoneal carcinoma
  2. First disease recurrence >6 months after first-line platinum-based chemotherapy
  3. Patients with measurable or non-measurable disease (RECIST v1.1) or CA 125 assessable disease (GCIG criteria) or histological proven diagnosis of relapse
  4. In case of cytoreductive surgery for recurrence, patients must be able to commence cytotoxic chemo-therapy within 8 weeks after cytoreductive surgery
  5. ECOG PS 0-2
  6. Absolute Neutrophil Count >= 1.5 x 10^9/L; Platelets >= 100 x 10^9/L; Hemoglobin >= 9.5 g/dL
  7. Patients not receiving anticoagulant medication who have an International Normalized Ratio <= 1.5 and an Activated ProThrombin Time <= 1.5 x ULN
  8. Serum bilirubin <= 2 x ULN; Serum transaminases <= 2.5 x ULN (<= 5 x ULN in the presence of liver metastasis)
  9. Serum creatinine < 1.6 mg/dL or creatinine clearance >= 40 mL/min; Glomerular filtration rate > 40 ml/min (estimates based on the Cockroft-Gault or Jelliffe formula); Urine dipstick for proteinuria < 2+. If urine dipstick is >= 2+, 24 hour urine collection must demonstrate <= 1 g of protein in 24 hours
  10. Normal blood pressure or adequately treated and controlled hypertension (either systolic BP ≤ 140 mmHg and/or diastolic BP ≤ 90 mmHg)

Exclusion Criteria:

  1. Ovarian tumors of low malignant potential
  2. Malignancies other than ovarian cancer within 5 years prior to randomization
  3. Administration of other simultaneous chemotherapy drugs, any other anticancer therapy or anti-neoplastic hormonal therapy, or simultaneous radiotherapy during the trial treatment period
  4. Any previous radiotherapy to the abdomen or pelvis
  5. Known hypersensitivity to used chemotherapeutic agents in this trial and bevacizumab and its excipients, chinese hamster ovary cell products or other recombinant human or humanised antibodies
  6. Current or recent chronic use of aspirin > 325 mg/day
  7. Surgery (including open biopsy) within 4 weeks prior to anticipated first dose of Bevacizumab
  8. History of VEGF therapy related abdominal fistula or gastrointestinal perforation
  9. Current, clinically relevant bowel obstruction, including sub-occlusive disease, related to underlying disease
  10. Patients with evidence of abdominal free air not explained by paracentesis or recent surgical procedure
  11. Previous Cerebro-Vascular Accident , Transient Ischaemic Attack or Sub-Arachnoid Haemorrhage
  12. Prior history of hypertensive crisis or hypertensive encephalopathy
  13. Clinically significant disease, including: myocardial infarction or unstable angina within ≤ 6 months of randomization; New York Heart Association (NYHA) >= grade 2 Congestive Heart Failure; poorly controlled cardiac arrhythmia despite medication; peripheral vascular disease grade >= 3
  14. LVEF defined by ECHO/MUGA below the institutional lower limit of normal
  15. Significant traumatic injury during 4 weeks prior to randomization
  16. Current brain metastases or spinal cord compression
  17. History or evidence upon neurological examination of central nervous system disease
  18. Non-healing wound, active ulcer or bone fracture
  19. History or evidence of thrombotic or hemorrhagic disorders within 6 months prior to randomization
  20. Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic coagulation)
  21. Fertile woman of childbearing potential not willing to use adequate contraception (oral contraceptives, intrauterine device or barrier method of contraception in conjunction with spermicidal jelly or surgically sterile) for the duration of the trial and at least 6 months afterwards
  22. Pregnant or lactating women
  23. Requirement of therapeutic anticoagulation using marcumar, warfarin or PTT-prolonging heparin

Sites / Locations

  • Bankstown-Lidcombe Hospital
  • Chris O'Brien Lifehouse
  • NCCI - Coffs Harbour Hospital
  • The Townsville Hospital
  • Peninsula Health - Frankston Hospital
  • Andrew Love Cancer Centre Geelong
  • Royal Brisbane & Women's Hospital
  • Royal Hobart Hospital
  • St. George Hospital
  • ICON Cancer Care Centre
  • Nambour General Hospital
  • Sir Charles Gairdner
  • North Coast Cancer Institute
  • Royal Hospital for Women
  • Mater Adult Hospital
  • Gold Coast University Hospital
  • Royal North Shore Hospital
  • St. John of God Hospital
  • Border Medical Oncology
  • MUG-Universitätsklinik für Frauenheilkunde Graz
  • MUI-Universität für Frauenheilkunde
  • AKH Linz
  • BHS Linz
  • SALK-LKH Salzburg, Universitätsklinik für Frauenheilkunde und Geburtshilfe
  • MUW-AKH Wien
  • UZ Leuven
  • ICO Paul Papin
  • Institut Sainte Catherine
  • Centre Hospitalier de Blois
  • Clinique Tivoli
  • Polyclinique Bordeaux Nord
  • Centre Francois Baclesse
  • Centre Hospitalier William Morey
  • Centre Hospitalier de Cholet
  • Hôpital Antoine Béclère
  • Centre Jean Perrin
  • Centre Hospitalier la Dracénie
  • Centre Hospitalier Général de Gap
  • Groupe Hospitalier Mutualiste de Grenoble
  • Hôpital Michallon, Centre Hospitalier Universitaire de Grenoble
  • Centre Hospitalier Départemental Les Oudairies
  • Institut d'Oncologie Hartmann
  • Centre Oscar Lambret
  • Hôpital Privé Clairval
  • Institute Paoli Clamettes
  • Hôpital Mercy
  • Hôpital de Mont-de-Marsan
  • ICM Val d'Aurelle
  • Hôpital Emile Muller
  • Centre d'Oncologie de Gentilly
  • Centre Catherine de Sienne
  • Centre Hospitalier Régional d'Orleans
  • Group Hospitalier Saint-Joseph
  • Centre Catalan d'Oncologie
  • Clinique Francheville
  • Centre Eugène Marquis
  • HôpitauxDrôme Nord - Site de Ramons
  • Centre Henri Becquerel
  • Clinique Armoricaine de Radiologie
  • ICO Centre René Gauducheau
  • Clinique Mutualiste de l'Estuaire, Cité Sanitaire
  • Centre Paul Strauss
  • Hôpitaux Universitaires de Strasbourg
  • Centre Hospitalier de Thonon-les-Bains
  • Clinique Pasteur
  • Clinique Saint Jean du Languedoc
  • Centre Hospitalier Bretagne Atlantique
  • Hôpital Privé Villeneuve d'Ascq, Institut de Canérologie
  • Kreisklinik Altötting-Burghausen
  • Klinikum St. Marien
  • Klinikum Aschaffenburg
  • Klinikum Augsburg
  • Hochtaunus-Klinik
  • Charité - Universitätsmedizin Berlin
  • HELIOS Klinikum Berlin-Buch
  • Praxisklinik Krebsheilkunde für Frauen
  • Augusta-Kranken-Anstalt Bochum
  • Johanniter-Krankenhaus
  • Medizinisches Zentrum Bonn-Friedensplatz
  • Schwerpunktpraxis für Onkologie / Hämatologie
  • Städtisches Klinikum Brandenburg
  • Gynäkologisch-Onkologische Gemeinschaftspraxis
  • DIAKO Ev. Diakonie-Krankenhaus
  • Gynaekologicum Bremen
  • Klinikum Bremen-Mitte
  • Klinikum Chemnitz
  • Klinikum Darmstadt
  • Donau-Isar-Kliniken, Klinikum Deggendorf
  • Städtisches Klinikum Dessau
  • Klinikum Dortmund
  • Onkozentrum Dresden
  • Universitätsklinikum Carl Gustav Carus
  • Evangelisches Krankenhaus Düsseldorf
  • Kaiserswerther Diakonie, Florence-Nightingale-Krankenhaus
  • Universitätsfrauenklinik Düsseldorf
  • Rottal-Inn-Klinik Eggenfelden
  • Universitätsklinikum Erlangen
  • Klinikum Essen Mitte
  • Universitätsklinikum Essen
  • Klinikum Esslingen
  • DIAKO Flensburg
  • Agaplesion Markus Krankenhaus
  • Klinikum Frankfurt Höchst
  • Universitätsklinikum Frankfurt
  • Universitätsfrauenklinik Freiburg
  • Kreiskrankenhaus Freudenstadt
  • Klinikum Fürth
  • Franziskus-Hospital Harderberg
  • HELIOS-Klinikum Gifhorn
  • Onkologische Kooperation Harz
  • Die Frauenarztpraxis in Grafing
  • Universitätsmedizin Greifswald
  • Universitätsklinikum Halle
  • Albertinen Krankenhaus
  • Marienkrankenhaus Hamburg
  • Universitätsklinikum Hamburg-Eppendorf
  • Sana-Klinikum Hameln-Pyrmont
  • Klinikum Hanau
  • Friederikenstift
  • Gynäkologisch-Onkologische Praxis Hannover
  • Medizinische Hochschule Hannover
  • Universitätsklinikum Heidelberg
  • Paracelsus-Klinik
  • Praxis Dres. Uleer / Pourfard
  • Klinikum Itzehoe
  • Universitätsklinikum Jena
  • St. Vincentius Kliniken
  • Klinikum Kassel
  • Klinikum Kempten
  • Universitätsklinikum Schleswig-Holstein
  • Zentrum für Gynäkologische Onkologie
  • Klinikum Konstanz
  • Klinikum Kulmbach
  • St. Elisabeth-Krankenhaus Hohenlind
  • Universitätsklinikum Köln
  • Asklepios Klinik Lich
  • St. Vincenz Krankenhaus
  • Universitätsklinikum Schleswig-Holstein, Campus Lübeck
  • Onkologische Schwerpunktpraxis Lüneburg
  • Klinik St. Marienstift
  • Universitätsklinikum Magdeburg
  • Universitätsmedizin Mainz
  • Universitätsfrauenklinik Mannheim
  • Universitätsklinikum Gießen und Marburg
  • Johannes Wesling Klinikum
  • Klinikum rechts der Isar
  • LMU München, Frauenklinik Großhadern
  • Rotkreuzklinikum München
  • Universitätsklinikum Münster
  • Kliniken des Landkreises Neumarkt
  • Lukaskrankenhaus
  • MVZ Nordhausen
  • Klinikum Nürnberg
  • Klinikum Offenbach
  • Ortenau-Klinikum
  • Marienhospital
  • St. Vincenz Krankenhaus
  • Onkologische Praxis Pinneberg
  • Harzklinikum Quedlinburg
  • Onkologie Ravensburg
  • imland Klinik Rendsburg
  • Klinikum am Steinenberg
  • Universitätsfrauenklinik Rostock
  • Thüringen-Kliniken
  • Caritasklinikum St. Theresia
  • Praxis Dr. med. W. Dietz
  • Leopoldina-Krankenhaus
  • HELIOS Kliniken Schwerin
  • Diakonie-Klinikum Schwäbisch Hall
  • Diakonie Klinikum Jung-Stilling
  • Klinikum Schaumburg, Krankenhaus Stadthagen
  • Klinikum Starnberg
  • g.Sund Gyn. Kompetenzzentrum
  • Marienhospital Stuttgart
  • Robert-Bosch-Krankenhaus
  • SRH Zentralklinikum Suhl
  • Kreiskrankenhaus "J. Kentmann"
  • Klinikum Traunstein
  • Klinikum Mutterhaus
  • Universitätsklinikum Tübingen
  • Universitätsfrauenklinik Ulm
  • Praxis Dr. med. W. W. Reiter
  • Schwarzwald-Baar Klinikum Villingen-Schwenningen
  • Lahn-Dill-Kliniken Wetzlar
  • Dr. Horst Schmidt Kliniken
  • St. Josefs Hospital Wiesbaden
  • amO am Klieversberg
  • Klinikum Worms
  • Heinrich-Braun-Klinikum
  • Gwynedd Hospital
  • Velindre Cancer Centre
  • The Beatson West of Scotland Cancer Center
  • Glan Clywd Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Control Arm

Research Arm

Arm Description

Patients receive bevacizumab 15 mg/kg iv on day 1 followed by gemcitabine 1000mg/m² iv on day 1 & 8 and carboplatin AUC4 iv on day 1 every 3 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities. Patients then continue to receive bevacizumab 15 mg/kg iv every 3 weeks until progression disease or unacceptable toxicities.

Patients receive bevacizumab 10 mg/kg iv on day 1 & 15 followed by PLD 30mg/m² iv on day 1 carboplatin AUC4 iv on day 1 every 4 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities. Patients then continue to receive bevacizumab 15 mg/kg iv every 3 weeks until progression disease or unacceptable toxicities.

Outcomes

Primary Outcome Measures

investigator-determined progression-free survival

Secondary Outcome Measures

biological progression-free survival by serum CA 125
Health related Quality of Life (QoL)
Safety and Tolerability, i.e. type, frequency, severity and duration o adverse reactions
Overall Survival

Full Information

First Posted
April 16, 2013
Last Updated
July 8, 2021
Sponsor
AGO Research GmbH
Collaborators
Arbeitsgemeinschaft Gynaekologische Onkologie Austria, ARCAGY/ GINECO GROUP, Australia New Zealand Gynaecological Oncology Group, Scottish Gynaecological Cancer Study Group
search

1. Study Identification

Unique Protocol Identification Number
NCT01837251
Brief Title
Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Official Title
A Prospective Randomized Phase III Trial of Carboplatin/Gemcitabine/Bevacizumab vs. Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
July 2021
Overall Recruitment Status
Completed
Study Start Date
May 2013 (Actual)
Primary Completion Date
January 2021 (Actual)
Study Completion Date
January 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AGO Research GmbH
Collaborators
Arbeitsgemeinschaft Gynaekologische Onkologie Austria, ARCAGY/ GINECO GROUP, Australia New Zealand Gynaecological Oncology Group, Scottish Gynaecological Cancer Study Group

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Evaluation of the best therapeutic index for patients with platinum-sensitive ovarian cancer when treatment with bevacizumab and gemcitabine/carboplatin or with bevacizumab and PLD/carboplatin.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Recurrent Platinum-sensitive Ovarian Cancer
Keywords
Ovarian Carcinoma, Bevacizumab, Gemcitabine, PLD, pegylated liposomal doxorubicin, Carboplatin, best therapeutic index, progression-free survival

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
682 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control Arm
Arm Type
No Intervention
Arm Description
Patients receive bevacizumab 15 mg/kg iv on day 1 followed by gemcitabine 1000mg/m² iv on day 1 & 8 and carboplatin AUC4 iv on day 1 every 3 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities. Patients then continue to receive bevacizumab 15 mg/kg iv every 3 weeks until progression disease or unacceptable toxicities.
Arm Title
Research Arm
Arm Type
Experimental
Arm Description
Patients receive bevacizumab 10 mg/kg iv on day 1 & 15 followed by PLD 30mg/m² iv on day 1 carboplatin AUC4 iv on day 1 every 4 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities. Patients then continue to receive bevacizumab 15 mg/kg iv every 3 weeks until progression disease or unacceptable toxicities.
Intervention Type
Drug
Intervention Name(s)
Carboplatin
Intervention Type
Drug
Intervention Name(s)
PLD
Intervention Type
Biological
Intervention Name(s)
Bevacizumab
Primary Outcome Measure Information:
Title
investigator-determined progression-free survival
Time Frame
every 12 weeks until progression or up to 30 months (whichever occurs first)
Secondary Outcome Measure Information:
Title
biological progression-free survival by serum CA 125
Time Frame
every 3 weeks until progression or up to 30 months (whichever occurs first)
Title
Health related Quality of Life (QoL)
Time Frame
Baseline and then every 12 weeks until investigator-determined progresssion-free survival and thereafter at every visit for th 5-years follow-up or death (whichever occurs first)
Title
Safety and Tolerability, i.e. type, frequency, severity and duration o adverse reactions
Time Frame
every 3 weeks, 30 months after start of treatment or if applicable 4 weeks after last dose of bevacizumab (whichever occurs later)
Title
Overall Survival
Time Frame
every 3 weeks during treatment with bevacizumab, thereafter every 6 months; for up 30 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically confirmed diagnosis of epithelial ovarian carcinoma or fallopian tube carcinoma or primary peritoneal carcinoma First disease recurrence >6 months after first-line platinum-based chemotherapy Patients with measurable or non-measurable disease (RECIST v1.1) or CA 125 assessable disease (GCIG criteria) or histological proven diagnosis of relapse In case of cytoreductive surgery for recurrence, patients must be able to commence cytotoxic chemo-therapy within 8 weeks after cytoreductive surgery ECOG PS 0-2 Absolute Neutrophil Count >= 1.5 x 10^9/L; Platelets >= 100 x 10^9/L; Hemoglobin >= 9.5 g/dL Patients not receiving anticoagulant medication who have an International Normalized Ratio <= 1.5 and an Activated ProThrombin Time <= 1.5 x ULN Serum bilirubin <= 2 x ULN; Serum transaminases <= 2.5 x ULN (<= 5 x ULN in the presence of liver metastasis) Serum creatinine < 1.6 mg/dL or creatinine clearance >= 40 mL/min; Glomerular filtration rate > 40 ml/min (estimates based on the Cockroft-Gault or Jelliffe formula); Urine dipstick for proteinuria < 2+. If urine dipstick is >= 2+, 24 hour urine collection must demonstrate <= 1 g of protein in 24 hours Normal blood pressure or adequately treated and controlled hypertension (either systolic BP ≤ 140 mmHg and/or diastolic BP ≤ 90 mmHg) Exclusion Criteria: Ovarian tumors of low malignant potential Malignancies other than ovarian cancer within 5 years prior to randomization Administration of other simultaneous chemotherapy drugs, any other anticancer therapy or anti-neoplastic hormonal therapy, or simultaneous radiotherapy during the trial treatment period Any previous radiotherapy to the abdomen or pelvis Known hypersensitivity to used chemotherapeutic agents in this trial and bevacizumab and its excipients, chinese hamster ovary cell products or other recombinant human or humanised antibodies Current or recent chronic use of aspirin > 325 mg/day Surgery (including open biopsy) within 4 weeks prior to anticipated first dose of Bevacizumab History of VEGF therapy related abdominal fistula or gastrointestinal perforation Current, clinically relevant bowel obstruction, including sub-occlusive disease, related to underlying disease Patients with evidence of abdominal free air not explained by paracentesis or recent surgical procedure Previous Cerebro-Vascular Accident , Transient Ischaemic Attack or Sub-Arachnoid Haemorrhage Prior history of hypertensive crisis or hypertensive encephalopathy Clinically significant disease, including: myocardial infarction or unstable angina within ≤ 6 months of randomization; New York Heart Association (NYHA) >= grade 2 Congestive Heart Failure; poorly controlled cardiac arrhythmia despite medication; peripheral vascular disease grade >= 3 LVEF defined by ECHO/MUGA below the institutional lower limit of normal Significant traumatic injury during 4 weeks prior to randomization Current brain metastases or spinal cord compression History or evidence upon neurological examination of central nervous system disease Non-healing wound, active ulcer or bone fracture History or evidence of thrombotic or hemorrhagic disorders within 6 months prior to randomization Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic coagulation) Fertile woman of childbearing potential not willing to use adequate contraception (oral contraceptives, intrauterine device or barrier method of contraception in conjunction with spermicidal jelly or surgically sterile) for the duration of the trial and at least 6 months afterwards Pregnant or lactating women Requirement of therapeutic anticoagulation using marcumar, warfarin or PTT-prolonging heparin
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jacobus Pfisterer, PhD MD
Organizational Affiliation
AGO Study Group
Official's Role
Study Chair
Facility Information:
Facility Name
Bankstown-Lidcombe Hospital
City
Bankstown
Country
Australia
Facility Name
Chris O'Brien Lifehouse
City
Camperdown
Country
Australia
Facility Name
NCCI - Coffs Harbour Hospital
City
Coffs Harbour
Country
Australia
Facility Name
The Townsville Hospital
City
Douglas
Country
Australia
Facility Name
Peninsula Health - Frankston Hospital
City
Frankston
Country
Australia
Facility Name
Andrew Love Cancer Centre Geelong
City
Geelong
Country
Australia
Facility Name
Royal Brisbane & Women's Hospital
City
Herston
Country
Australia
Facility Name
Royal Hobart Hospital
City
Hobart
Country
Australia
Facility Name
St. George Hospital
City
Kogarah
Country
Australia
Facility Name
ICON Cancer Care Centre
City
Milton
Country
Australia
Facility Name
Nambour General Hospital
City
Nambour
Country
Australia
Facility Name
Sir Charles Gairdner
City
Nedlands
Country
Australia
Facility Name
North Coast Cancer Institute
City
Port Macquarie
Country
Australia
Facility Name
Royal Hospital for Women
City
Randwick
Country
Australia
Facility Name
Mater Adult Hospital
City
South Brisbane
Country
Australia
Facility Name
Gold Coast University Hospital
City
Southport
Country
Australia
Facility Name
Royal North Shore Hospital
City
St. Leonards
Country
Australia
Facility Name
St. John of God Hospital
City
Subiaco
Country
Australia
Facility Name
Border Medical Oncology
City
Wodonga
Country
Australia
Facility Name
MUG-Universitätsklinik für Frauenheilkunde Graz
City
Graz
Country
Austria
Facility Name
MUI-Universität für Frauenheilkunde
City
Innsbruck
Country
Austria
Facility Name
AKH Linz
City
Linz
Country
Austria
Facility Name
BHS Linz
City
Linz
Country
Austria
Facility Name
SALK-LKH Salzburg, Universitätsklinik für Frauenheilkunde und Geburtshilfe
City
Salzburg
Country
Austria
Facility Name
MUW-AKH Wien
City
Wien
Country
Austria
Facility Name
UZ Leuven
City
Leuven
Country
Belgium
Facility Name
ICO Paul Papin
City
Angers
Country
France
Facility Name
Institut Sainte Catherine
City
Avignon
Country
France
Facility Name
Centre Hospitalier de Blois
City
Blois
Country
France
Facility Name
Clinique Tivoli
City
Bordeaux
Country
France
Facility Name
Polyclinique Bordeaux Nord
City
Bordeaux
Country
France
Facility Name
Centre Francois Baclesse
City
Caen
Country
France
Facility Name
Centre Hospitalier William Morey
City
Chalon-Sur-Saone
Country
France
Facility Name
Centre Hospitalier de Cholet
City
Cholet
Country
France
Facility Name
Hôpital Antoine Béclère
City
Clamart
Country
France
Facility Name
Centre Jean Perrin
City
Clermont-Ferrand
Country
France
Facility Name
Centre Hospitalier la Dracénie
City
Draguignan
Country
France
Facility Name
Centre Hospitalier Général de Gap
City
Gap
Country
France
Facility Name
Groupe Hospitalier Mutualiste de Grenoble
City
Grenoble
Country
France
Facility Name
Hôpital Michallon, Centre Hospitalier Universitaire de Grenoble
City
Grenoble
Country
France
Facility Name
Centre Hospitalier Départemental Les Oudairies
City
La Roche sur Yon
Country
France
Facility Name
Institut d'Oncologie Hartmann
City
Levallois-Perret
Country
France
Facility Name
Centre Oscar Lambret
City
Lille
Country
France
Facility Name
Hôpital Privé Clairval
City
Marseille
Country
France
Facility Name
Institute Paoli Clamettes
City
Marseille
Country
France
Facility Name
Hôpital Mercy
City
Metz
Country
France
Facility Name
Hôpital de Mont-de-Marsan
City
Mont de Marsan
Country
France
Facility Name
ICM Val d'Aurelle
City
Montpellier
Country
France
Facility Name
Hôpital Emile Muller
City
Mulhouse
Country
France
Facility Name
Centre d'Oncologie de Gentilly
City
Nancy
Country
France
Facility Name
Centre Catherine de Sienne
City
Nantes
Country
France
Facility Name
Centre Hospitalier Régional d'Orleans
City
Orleans
Country
France
Facility Name
Group Hospitalier Saint-Joseph
City
Paris
Country
France
Facility Name
Centre Catalan d'Oncologie
City
Perpignan
Country
France
Facility Name
Clinique Francheville
City
Périgueux
Country
France
Facility Name
Centre Eugène Marquis
City
Rennes
Country
France
Facility Name
HôpitauxDrôme Nord - Site de Ramons
City
Romans-sur-Isère
Country
France
Facility Name
Centre Henri Becquerel
City
Rouen
Country
France
Facility Name
Clinique Armoricaine de Radiologie
City
Saint Brieuc
Country
France
Facility Name
ICO Centre René Gauducheau
City
Saint Herblain
Country
France
Facility Name
Clinique Mutualiste de l'Estuaire, Cité Sanitaire
City
Saint Nazaire
Country
France
Facility Name
Centre Paul Strauss
City
Strasbourg
Country
France
Facility Name
Hôpitaux Universitaires de Strasbourg
City
Strasbourg
Country
France
Facility Name
Centre Hospitalier de Thonon-les-Bains
City
Thonon-les-Bains
Country
France
Facility Name
Clinique Pasteur
City
Toulouse
Country
France
Facility Name
Clinique Saint Jean du Languedoc
City
Toulouse
Country
France
Facility Name
Centre Hospitalier Bretagne Atlantique
City
Vannes
Country
France
Facility Name
Hôpital Privé Villeneuve d'Ascq, Institut de Canérologie
City
Villeneuve d'Ascq
Country
France
Facility Name
Kreisklinik Altötting-Burghausen
City
Altötting
Country
Germany
Facility Name
Klinikum St. Marien
City
Amberg
Country
Germany
Facility Name
Klinikum Aschaffenburg
City
Aschaffenburg
Country
Germany
Facility Name
Klinikum Augsburg
City
Augsburg
Country
Germany
Facility Name
Hochtaunus-Klinik
City
Bad Homburg
Country
Germany
Facility Name
Charité - Universitätsmedizin Berlin
City
Berlin
Country
Germany
Facility Name
HELIOS Klinikum Berlin-Buch
City
Berlin
Country
Germany
Facility Name
Praxisklinik Krebsheilkunde für Frauen
City
Berlin
Country
Germany
Facility Name
Augusta-Kranken-Anstalt Bochum
City
Bochum
Country
Germany
Facility Name
Johanniter-Krankenhaus
City
Bonn
Country
Germany
Facility Name
Medizinisches Zentrum Bonn-Friedensplatz
City
Bonn
Country
Germany
Facility Name
Schwerpunktpraxis für Onkologie / Hämatologie
City
Bottrop
Country
Germany
Facility Name
Städtisches Klinikum Brandenburg
City
Brandenburg
Country
Germany
Facility Name
Gynäkologisch-Onkologische Gemeinschaftspraxis
City
Braunschweig
Country
Germany
Facility Name
DIAKO Ev. Diakonie-Krankenhaus
City
Bremen
Country
Germany
Facility Name
Gynaekologicum Bremen
City
Bremen
Country
Germany
Facility Name
Klinikum Bremen-Mitte
City
Bremen
Country
Germany
Facility Name
Klinikum Chemnitz
City
Chemnitz
Country
Germany
Facility Name
Klinikum Darmstadt
City
Darmstadt
Country
Germany
Facility Name
Donau-Isar-Kliniken, Klinikum Deggendorf
City
Deggendorf
Country
Germany
Facility Name
Städtisches Klinikum Dessau
City
Dessau
Country
Germany
Facility Name
Klinikum Dortmund
City
Dortmund
Country
Germany
Facility Name
Onkozentrum Dresden
City
Dresden
Country
Germany
Facility Name
Universitätsklinikum Carl Gustav Carus
City
Dresden
Country
Germany
Facility Name
Evangelisches Krankenhaus Düsseldorf
City
Düsseldorf
Country
Germany
Facility Name
Kaiserswerther Diakonie, Florence-Nightingale-Krankenhaus
City
Düsseldorf
Country
Germany
Facility Name
Universitätsfrauenklinik Düsseldorf
City
Düsseldorf
Country
Germany
Facility Name
Rottal-Inn-Klinik Eggenfelden
City
Eggenfelden
Country
Germany
Facility Name
Universitätsklinikum Erlangen
City
Erlangen
Country
Germany
Facility Name
Klinikum Essen Mitte
City
Essen
Country
Germany
Facility Name
Universitätsklinikum Essen
City
Essen
Country
Germany
Facility Name
Klinikum Esslingen
City
Esslingen
Country
Germany
Facility Name
DIAKO Flensburg
City
Flensburg
Country
Germany
Facility Name
Agaplesion Markus Krankenhaus
City
Frankfurt
Country
Germany
Facility Name
Klinikum Frankfurt Höchst
City
Frankfurt
Country
Germany
Facility Name
Universitätsklinikum Frankfurt
City
Frankfurt
Country
Germany
Facility Name
Universitätsfrauenklinik Freiburg
City
Freiburg
Country
Germany
Facility Name
Kreiskrankenhaus Freudenstadt
City
Freudenstadt
Country
Germany
Facility Name
Klinikum Fürth
City
Fürth
Country
Germany
Facility Name
Franziskus-Hospital Harderberg
City
Georgsmarienhütte
Country
Germany
Facility Name
HELIOS-Klinikum Gifhorn
City
Gifhorn
Country
Germany
Facility Name
Onkologische Kooperation Harz
City
Goslar
Country
Germany
Facility Name
Die Frauenarztpraxis in Grafing
City
Grafing
Country
Germany
Facility Name
Universitätsmedizin Greifswald
City
Greifswald
Country
Germany
Facility Name
Universitätsklinikum Halle
City
Halle
Country
Germany
Facility Name
Albertinen Krankenhaus
City
Hamburg
Country
Germany
Facility Name
Marienkrankenhaus Hamburg
City
Hamburg
Country
Germany
Facility Name
Universitätsklinikum Hamburg-Eppendorf
City
Hamburg
Country
Germany
Facility Name
Sana-Klinikum Hameln-Pyrmont
City
Hameln
Country
Germany
Facility Name
Klinikum Hanau
City
Hanau
Country
Germany
Facility Name
Friederikenstift
City
Hannover
Country
Germany
Facility Name
Gynäkologisch-Onkologische Praxis Hannover
City
Hannover
Country
Germany
Facility Name
Medizinische Hochschule Hannover
City
Hannover
Country
Germany
Facility Name
Universitätsklinikum Heidelberg
City
Heidelberg
Country
Germany
Facility Name
Paracelsus-Klinik
City
Henstedt-Ulzburg
Country
Germany
Facility Name
Praxis Dres. Uleer / Pourfard
City
Hildesheim
Country
Germany
Facility Name
Klinikum Itzehoe
City
Itzehoe
Country
Germany
Facility Name
Universitätsklinikum Jena
City
Jena
Country
Germany
Facility Name
St. Vincentius Kliniken
City
Karlsruhe
Country
Germany
Facility Name
Klinikum Kassel
City
Kassel
Country
Germany
Facility Name
Klinikum Kempten
City
Kempten
Country
Germany
Facility Name
Universitätsklinikum Schleswig-Holstein
City
Kiel
Country
Germany
Facility Name
Zentrum für Gynäkologische Onkologie
City
Kiel
Country
Germany
Facility Name
Klinikum Konstanz
City
Konstanz
Country
Germany
Facility Name
Klinikum Kulmbach
City
Kulmbach
Country
Germany
Facility Name
St. Elisabeth-Krankenhaus Hohenlind
City
Köln
Country
Germany
Facility Name
Universitätsklinikum Köln
City
Köln
Country
Germany
Facility Name
Asklepios Klinik Lich
City
Lich
Country
Germany
Facility Name
St. Vincenz Krankenhaus
City
Limburg
Country
Germany
Facility Name
Universitätsklinikum Schleswig-Holstein, Campus Lübeck
City
Lübeck
Country
Germany
Facility Name
Onkologische Schwerpunktpraxis Lüneburg
City
Lüneburg
Country
Germany
Facility Name
Klinik St. Marienstift
City
Magdeburg
Country
Germany
Facility Name
Universitätsklinikum Magdeburg
City
Magdeburg
Country
Germany
Facility Name
Universitätsmedizin Mainz
City
Mainz
Country
Germany
Facility Name
Universitätsfrauenklinik Mannheim
City
Mannheim
Country
Germany
Facility Name
Universitätsklinikum Gießen und Marburg
City
Marburg
Country
Germany
Facility Name
Johannes Wesling Klinikum
City
Minden
Country
Germany
Facility Name
Klinikum rechts der Isar
City
München
Country
Germany
Facility Name
LMU München, Frauenklinik Großhadern
City
München
Country
Germany
Facility Name
Rotkreuzklinikum München
City
München
Country
Germany
Facility Name
Universitätsklinikum Münster
City
Münster
Country
Germany
Facility Name
Kliniken des Landkreises Neumarkt
City
Neumarkt
Country
Germany
Facility Name
Lukaskrankenhaus
City
Neuss
Country
Germany
Facility Name
MVZ Nordhausen
City
Nordhausen
Country
Germany
Facility Name
Klinikum Nürnberg
City
Nürnberg
Country
Germany
Facility Name
Klinikum Offenbach
City
Offenbach
Country
Germany
Facility Name
Ortenau-Klinikum
City
Offenburg
Country
Germany
Facility Name
Marienhospital
City
Osnabrück
Country
Germany
Facility Name
St. Vincenz Krankenhaus
City
Paderborn
Country
Germany
Facility Name
Onkologische Praxis Pinneberg
City
Pinneberg
Country
Germany
Facility Name
Harzklinikum Quedlinburg
City
Quedlinburg
Country
Germany
Facility Name
Onkologie Ravensburg
City
Ravensburg
Country
Germany
Facility Name
imland Klinik Rendsburg
City
Rendsburg
Country
Germany
Facility Name
Klinikum am Steinenberg
City
Reutlingen
Country
Germany
Facility Name
Universitätsfrauenklinik Rostock
City
Rostock
Country
Germany
Facility Name
Thüringen-Kliniken
City
Saalfeld
Country
Germany
Facility Name
Caritasklinikum St. Theresia
City
Saarbrücken
Country
Germany
Facility Name
Praxis Dr. med. W. Dietz
City
Salzgitter
Country
Germany
Facility Name
Leopoldina-Krankenhaus
City
Schweinfurt
Country
Germany
Facility Name
HELIOS Kliniken Schwerin
City
Schwerin
Country
Germany
Facility Name
Diakonie-Klinikum Schwäbisch Hall
City
Schwäbisch Hall
Country
Germany
Facility Name
Diakonie Klinikum Jung-Stilling
City
Siegen
Country
Germany
Facility Name
Klinikum Schaumburg, Krankenhaus Stadthagen
City
Stadthagen
Country
Germany
Facility Name
Klinikum Starnberg
City
Starnberg
Country
Germany
Facility Name
g.Sund Gyn. Kompetenzzentrum
City
Stralsund
Country
Germany
Facility Name
Marienhospital Stuttgart
City
Stuttgart
Country
Germany
Facility Name
Robert-Bosch-Krankenhaus
City
Stuttgart
Country
Germany
Facility Name
SRH Zentralklinikum Suhl
City
Suhl
Country
Germany
Facility Name
Kreiskrankenhaus "J. Kentmann"
City
Torgau
Country
Germany
Facility Name
Klinikum Traunstein
City
Traunstein
Country
Germany
Facility Name
Klinikum Mutterhaus
City
Trier
Country
Germany
Facility Name
Universitätsklinikum Tübingen
City
Tübingen
Country
Germany
Facility Name
Universitätsfrauenklinik Ulm
City
Ulm
Country
Germany
Facility Name
Praxis Dr. med. W. W. Reiter
City
Viersen
Country
Germany
Facility Name
Schwarzwald-Baar Klinikum Villingen-Schwenningen
City
Villingen-Schwenningen
Country
Germany
Facility Name
Lahn-Dill-Kliniken Wetzlar
City
Wetzlar
Country
Germany
Facility Name
Dr. Horst Schmidt Kliniken
City
Wiesbaden
Country
Germany
Facility Name
St. Josefs Hospital Wiesbaden
City
Wiesbaden
Country
Germany
Facility Name
amO am Klieversberg
City
Wolfsburg
Country
Germany
Facility Name
Klinikum Worms
City
Worms
Country
Germany
Facility Name
Heinrich-Braun-Klinikum
City
Zwickau
Country
Germany
Facility Name
Gwynedd Hospital
City
Bangor
Country
United Kingdom
Facility Name
Velindre Cancer Centre
City
Cardiff
Country
United Kingdom
Facility Name
The Beatson West of Scotland Cancer Center
City
Glasgow
Country
United Kingdom
Facility Name
Glan Clywd Hospital
City
Rhyl
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
32305099
Citation
Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marme F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE; AGO-OVAR 2.21/ENGOT-ov 18 Investigators. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 2020 May;21(5):699-709. doi: 10.1016/S1470-2045(20)30142-X. Epub 2020 Apr 16. Erratum In: Lancet Oncol. 2022 Jun;23(6):e248.
Results Reference
result
Links:
URL
http://www.ago-ovar.de
Description
Homepage of AGO Study Group

Learn more about this trial

Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

We'll reach out to this number within 24 hrs